The site is temporarily down due to maintenance. Sorry for the inconvenience.

The site is temporarily down due to maintenance. Sorry for the inconvenience.

Quality & Accuracy


The latest technologies

Speed ​​&

Factor V Leiden mutation

Also known as: factor V Leiden mutation
SKU: 714


Study material: Venous blood
Response time (working day): 14
The test is done on an empty stomach: Yes
Home call service: Yes
Country: EU

General Information


Thrombophilia is a condition caused by congenital or acquired pathologies, during which the ability of blood to clot increases. Clinical manifestations of thrombophilia are: thromboembolic disease, repeated spontaneous abortions, pregnancy complications (eclampsia, preeclampsia, fetal growth retardation, placental apoplexy, stillbirth, premature birth), acute coronary syndrome, aseptic necrosis of the femoral head.

Almost half of cases of hereditary thrombophilia are due to factor V and prothrombin gene G20210a mutation.

Factor V Leiden mutation is an abnormal variant of factor V that is resistant to activated protein C. It is the result of a point mutation that occurs in the long arm of the first chromosome. The resulting factor V is called the Leyden factor. As a result of this mutation, Leiden factor V activity decreases 10 times compared to the norm and persists (delays) in the blood stream, which increases the risk of blood clots.

The mutation is transmitted in an autosomal codominant way (both alleles (copy) of the gene equally exhibit the properties and synthesize the characteristic protein) and the incidence of genetic thrombophilia is the cause of 3-7%.

The risk of thrombosis depends on whether the individual is homozygous or heterozygous for the mutation. In heterozygous individuals, compared to normal factor V, the risk increases by 4-8 times, and in homozygotes by 80-100-fold.

The risk of thrombosis is further increased by the coexistence of pathologies of other coagulation factors: protein c, protein s deficiency, MTHFR gene mutation (associated with hyperhomocysteinemia), oral contraception, pregnancy and others.

Study material: Venous blood

Method: PCR - real-time (by real-time detection of accumulated PCR material), genotyping at the end of the study.


  1. Homozygous wild type (no Leiden mutation)
  2. Heterozygous genotype (contains wild-type healthy and mutated alleles)
  3. Homozygous mutated genotype (contains both mutated alleles)

Additional information

Testing process

Purchase a test Submission of material

Purchase a test

Submission of material

Results Online Consult a doctor

Results Online

Consult a doctor

Call Now Button